Oppenheimer analyst Justin Kim tells investors in a research note that the firm is bullish on Apellis after the company provided an update to its ongoing investigation for Syfovre and emerging rare cases of retinal vasculitis, and while a root cause remains unidentified, the company has noted variability of a 19-gauge filter needle within certain injection kits and recommendation of the 18-gauge in distribution. The firm, which made no change to its Outperform rating, expects GA to gain appreciation with uncertainty thinning.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Unusually active option classes on open August 23rd
- Apellis price target raised to $64 from $60 at UBS
- Apellis (NASDAQ:APLS) Soars After Giving Safety Update on Drug
- Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
- Apellis provides update on supplied injection kits